Anticoagulation Type and Early Recurrence in Cardioembolic Stroke

Supplemental Digital Content is available in the text. Background and Purpose: In patients with acute ischemic stroke and atrial fibrillation, treatment with low molecular weight heparin increases early hemorrhagic risk without reducing early recurrence, and there is limited data comparing warfarin to direct oral anticoagulant (DOAC) therapy. We aim to compare the effects of the treatments above on the risk of 90-day recurrent ischemic events and delayed symptomatic intracranial hemorrhage. Methods: We included consecutive patients with acute ischemic stroke and atrial fibrillation from the IAC (Initiation of Anticoagulation after Cardioembolic) stroke study pooling data from stroke registries of 8 comprehensive stroke centers across the United States. We compared recurrent ischemic events and delayed symptomatic intracranial hemorrhage between each of the following groups in separate Cox-regression analyses: (1) DOAC versus warfarin and (2) bridging with heparin/low molecular weight heparin versus no bridging, adjusting for pertinent confounders to test these associations. Results: We identified 1289 patients who met the bridging versus no bridging analysis inclusion criteria and 1251 patients who met the DOAC versus warfarin analysis inclusion criteria. In adjusted Cox-regression models, bridging (versus no bridging) treatment was associated with a high risk of delayed symptomatic intracranial hemorrhage (hazard ratio, 2.74 [95% CI, 1.01–7.42]) but a similar rate of recurrent ischemic events (hazard ratio, 1.23 [95% CI, 0.63–2.40]). Furthermore, DOAC (versus warfarin) treatment was associated with a lower risk of recurrent ischemic events (hazard ratio, 0.51 [95% CI, 0.29–0.87]) but not delayed symptomatic intracranial hemorrhage (hazard ratio, 0.57 [95% CI, 0.22–1.48]). Conclusions: Our study suggests that patients with ischemic stroke and atrial fibrillation would benefit from the initiation of a DOAC without bridging therapy. Due to our study limitations, these findings should be interpreted with caution pending confirmation from large prospective studies.

[1]  Eric E. Smith,et al.  Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. , 2019, JAMA neurology.

[2]  K. Furie,et al.  Anticoagulation After Stroke in Patients With Atrial Fibrillation. , 2019, Stroke.

[3]  D. Werring,et al.  Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation , 2019, Annals of neurology.

[4]  S. Warach,et al.  Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation , 2019, The Lancet Neurology.

[5]  Carol Coupland,et al.  Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care , 2018, British Medical Journal.

[6]  S. Mayer,et al.  Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2017, Stroke.

[7]  K. Furie,et al.  Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study , 2017, Journal of the American Heart Association.

[8]  Deborah M Caldwell,et al.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, BMJ.

[9]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[10]  R. Passman Time in Therapeutic Range in Warfarin-Treated Patients: Is Very Good Good Enough? , 2016, JAMA.

[11]  D. McManus,et al.  Atrial Fibrillation Is Associated With a Worse 90-Day Outcome Than Other Cardioembolic Stroke Subtypes , 2016, Stroke.

[12]  W. Ageno,et al.  Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing The RAF Study , 2015, Stroke.

[13]  B. Gersh,et al.  Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation , 2015, Circulation.

[14]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[15]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[16]  C. Kase,et al.  Factors influencing haemorrhagic transformation in ischaemic stroke , 2013, The Lancet Neurology.

[17]  P. Sandercock,et al.  Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials , 2013, The Lancet Neurology.

[18]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[19]  D. Berlowitz,et al.  Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation: Results of the Veterans Affairs Study To Improve Anticoagulation (VARIA) , 2011, Circulation. Cardiovascular quality and outcomes.

[20]  D. Leys,et al.  Asymptomatic Hemorrhagic Transformation of Infarction and Its Relationship With Functional Outcome and Stroke Subtype: Assessment From the Tinzaparin in Acute Ischaemic Stroke Trial , 2010, Stroke.

[21]  M. Mazzola,et al.  Frequency and Determinants for Hemorrhagic Transformation of Cerebral Infarction , 2009, Neuroepidemiology.

[22]  J. Grotta,et al.  Anticoagulation after cardioembolic stroke: to bridge or not to bridge? , 2008, Archives of neurology.

[23]  J. Arenillas,et al.  Timing of Spontaneous Recanalization and Risk of Hemorrhagic Transformation in Acute Cardioembolic Stroke , 2001, Stroke.

[24]  E. Berge,et al.  Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study , 2000, The Lancet.

[25]  E. Berge,et al.  Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. , 2000, Lancet.

[26]  A. Arboix,et al.  Clinical Predictors of Early Embolic Recurrence in Presumed Cardioembolic Stroke , 1998, Cerebrovascular Diseases.

[27]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[28]  J. Hirsh,et al.  Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.

[29]  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. , 1997, Lancet.

[30]  M. D. Freedman Oral Anticoagulants: Pharmacodynamics, Clinical Indications and Adverse Effects , 1992, Journal of clinical pharmacology.